EN4
规格
| Cas Number | 1197824-15-9 |
| 规格或纯度 | ≥98% |
| 纯度 | ≥98% |
| 包装 | 100mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 83 mg/mL (199.29 mM); Water: Insoluble; Ethanol: Insoluble; |
| 简短描述 | Myc 抑制剂 |
| 英文简短描述 | Myc Inhibitors |
| 过滤标签 | Apoptosis,c-Myc |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | EN4是一种针对MYC半胱氨酸171（C171）的共价配体，对c-MYC比对N-MYC和L-MYC有选择性。EN4 可抑制 MYC 的转录活性，下调 MYC 靶标，并抑制肿瘤发生。 |
| 英文描述 |
Information EN4 EN4, a covalent ligand that targets cysteine 171 (C171) of MYC , is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis. Targets MYC In vitro EN4 directly targets MYC in cells, reduces MYC and MAX thermal stability, inhibits MYC transcriptional activity, downregulates multiple MYC transcriptional targets, and impairs tumorigenesis. EN4 treatment significantly impairs 231MFP breast cancer cell proliferation in a dose- and time-dependent manner. EN4 impairs the cell survival of MYC transformed mammary epithelial MCF10A cells, but not parental MCF10A cells that are not dependent on MYC. In vivo EN4 treatment initiated after establishment of a 231MFP breast tumor xenograft in immune-deficient mice also significantly attenuates tumor growth in vivo. Cell Research(from reference) Cell lines：231MFP, MDA-MB-231, HEK293T and MCF10A cells Concentrations：50 μM Incubation Time：24 h |